Publications 2011 LMCT – Oncology Research Center

Goyvaerts C, De Groeve K, Dingemans J, Van Lint S, Robays L, Heirman C, Reiser J, Zhang X, Thielemans K, De Baetselier P, Raes G, Breckpot K. Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Therapy. In press.
A.M.T. Van Nuffel, D. Benteyn, S. Wilgenhof, J. Corthals, C. Heirman, B. Neyns, K. Thielemans, A. Bonehill. Combined intravenous and intradermal autologous TriMix-dendritic cell therapy resulting in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother. In press.
Allard SD, De Keersmaecker B, de Goede AL, Koetsveld J, Verschuren EJ, Reedijk ML, Wylock C, De Bel, AV, Vandeloo J, Pistoor F, Heirman C, Beyer WEP, Eilers P, Corthals J, Padmos I, Thielemans K, Osterhaus ADME, Lacor P, van der Ende ME, Aerts JL, van Baalen CA and Gruters RA. A phase I/IIa immunotherapy trial of HIV-1 infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol. In press.
De Keersmaecker B, Thielemans K and Aerts JL. Optimisation and immune monitoring of a dendritic cell based therapeutic HIV-1 vaccine. Belg J Hematol. 2011;2:119-21
Legutko A, Marichal T, Fiévez L, Bedoret D, Mayer A, de Vries H, Klotz L, Drion PV, Heirman C, Cataldo D, Louis R, Thielemans K, Andris F, Leo O, Lekeux P, Desmet CJ, Bureau F. Sirtuin 1 Promotes Th2 Responses and Airway Allergy by Repressing Peroxisome Proliferator-Activated Receptor-{gamma} Activity in Dendritic Cells. J Immunol. 2011 Nov 1;187(9):4517-29.
Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M, van Gele M, Thielemans K, Neyns B, Roche N, Verbeke N, Deron P, Speeckaert M, Brochez L. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer. 2011 Oct 25
Vanderlinden K, Wilgenhof S, Van De Winkel N, Geers C, Thielemans K, Neyns B, De Vogelaere K, Delvaux G. Long-term disease-free survival following dendritic cell therapy and resection of small bowel melanoma metastases – a case report. Anticancer Res. 2011 Oct;31(10):3579-83.
Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother. 2011 Jun;34(5):448-56.
Van Lint S, Thielemans K, Breckpot K. mRNA: delivering an antitumor message? Immunotherapy. 2011 May;3(5):605-7.
De Keersmaecker B, Heirman C, Corthals J, Empsen C, van Grunsven LA, Allard SD, Pen J, Lacor P, Thielemans K, Aerts JL. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. Leukoc Biol. 2011 Jun;89(6):989-99. Epub 2011 Mar 22
De Keersmaecker B, Heirman C, Corthals J, Empsen C, van Grunsven LA, Allard SD, Pen J, Lacor P, Thielemans K, Aerts JL. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol. 2011 Jun;89(6):989-99. Epub 2011 Mar 22.
Wilgenhof S, Pierret L, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, De Coninck A, Verfaillie G, Vandenbroucke F, Van Riet I, Bonehill A, Thielemans K, Neyns B. Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases. Melanoma Res. 2011 Apr;21(2):152-9.
Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother. 2011 Jan;60(1):23-35.